Share on StockTwits

USANA Health Sciences (NASDAQ:USNA) Insider Kevin Guest sold 10,160 shares of USANA Health Sciences stock in a transaction dated Thursday, May 22nd. The stock was sold at an average price of $71.15, for a total transaction of $722,884.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Separately, analysts at Zacks downgraded shares of USANA Health Sciences from an “outperform” rating to a “neutral” rating in a research note on Tuesday, April 8th. They now have a $79.50 price target on the stock. Three investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $79.38.

USANA Health Sciences (NASDAQ:USNA) traded up 0.28% on Tuesday, hitting $72.39. The stock had a trading volume of 118,633 shares. USANA Health Sciences has a one year low of $55.01 and a one year high of $92.00. The stock’s 50-day moving average is $73.30 and its 200-day moving average is $71.87. The company has a market cap of $1.008 billion and a price-to-earnings ratio of 13.30.

USANA Health Sciences (NASDAQ:USNA) last announced its earnings results on Tuesday, April 29th. The company reported $1.15 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.30 by $0.15. The company had revenue of $182.40 million for the quarter, compared to the consensus estimate of $185.85 million. During the same quarter in the previous year, the company posted $1.28 earnings per share. The company’s revenue for the quarter was up 7.9% on a year-over-year basis. On average, analysts predict that USANA Health Sciences will post $5.65 earnings per share for the current fiscal year.

USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.